Lauren MartinAssociateMcDermott Will & Emery Websitewww.mwe.comBlogwww.mwe.com/insightsConnectEmailTwitterLinkedIn312-984-6981 Professional Biography Lauren Martin is an associate in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Chicago office. She focuses her practice on intellectual property litigation. More Legal and Business Bylines From Lauren Martin Clinical Trial Hypothesis Doesn’t Constitute Reasonable Expectation of Success - (Posted On Friday, December 22, 2017) Claim to Gel Formulation Not Obvious Over Prior Art Liquid Formulation - (Posted On Saturday, November 25, 2017) Allied Mineral Products, Inc. v. Osmi, Inc: Foreign Suit against Customers Insufficient Grounds for US Declaratory Judgment Action by Manufacturer - (Posted On Tuesday, October 31, 2017) No Right to Discovery of Unidentified Patents During BPCIA Litigation - (Posted On Saturday, September 30, 2017) Cardiovascular Disease Correlation Doesn’t Beat § 101 Challenge: Cleveland Clinic Foundation v. True Health Diagnostics - (Posted On Tuesday, August 29, 2017) Prior Product Use Limits “Pharmaceutical Batches” Claims to Process Disclosed in Patent Example - (Posted On Wednesday, May 31, 2017) Exceptional Case Rulings Establish Deference to District Court’s Manifest - (Posted On Friday, April 28, 2017) Federal Circuit Evaluates PTAB Reliance on Expert Testimony to Satisfy Substantial Evidence - (Posted On Thursday, March 30, 2017) Evidence to Negate PGR Eligibility Based on Filing Date May Not Be Sufficient to Establish Filing Date for Purposes of Antedating Prior Art - (Posted On Wednesday, February 01, 2017) Intellectual Property: When Applying Alice, Evaluate Invention as Whole - (Posted On Monday, August 29, 2016) Pagination Page 1 Next page Next › Current Legal Analysis Updates to the Corporate Transparency Act's Beneficial Ownership Information Reporting Requirements by: Bryce Ellis , Keith Paul Bishop Corporate Transparency Act Enforcement Resumes with Extended Deadlines by: Kathleen M. Porter , Kiernan L. Ignacio CTA Injunction Stayed; FinCEN Extends Reporting Deadlines by: Corporate Compliance, Investigations and Defense Andrews Kurth CTA Revived: Corporate Transparency Act Injunction Lifted by Federal Court and Filing Deadlines Extended by: David E. Weiss , Virginia B. Wilson CMS Rule for CY 2026 Highlights AI, Behavioral Health, Anti-Obesity Drug Coverage, and More by: Helaine I. Fingold , Philo D. Hall Important Corporate Transparency Act Update by: Ryan A. Biller , Jeffrey M. Heller CTA Reporting Requirements Reinstated by: Evgeny Magidenko , Kevin Matz Urgent Update: Corporate Transparency Act Injunction Is Stayed and Mandatory Reporting Requirements Are Applicable to Reporting Companies as Early as January 13, 2025 by: Brian A. Haskel , Robert E. Schiappacasse Upcoming Events Jan 8 2025 Key Proposals in the CY2026 Medicare Advantage and Part D Proposed Rule Jan 8 2025 Whistleblower Protections: Navigating Health Care Employment & Labor Rights Jan 14 2025 What to Expect in Chemicals Policy and Regulation and on Capitol Hill in 2025 Jan 15 2025 Healthy AI Roundtable Chicago Jan 31 2025 Mass Actions: Bankruptcies, MDLs, Class Actions & Harrington v. Purdue Feb 26 2025 MCLE Triple Play Print
